These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Anticlastogenic effect of diosgenin on 7,12-dimethylbenz(a)anthracene treated experimental animals.
    Author: Rajalingam K, Sugunadevi G, Vijayaanand MA, Sathiyapriya J, Sivakumar K, Suresh K.
    Journal: Toxicol Mech Methods; 2013 Feb; 23(2):77-85. PubMed ID: 22901014.
    Abstract:
    The present investigation explores the anticlastogenic effect of diosgenin on 7,12-dimethylbenz(a)anthracene (DMBA) treated clastogenesis. The frequency of bone marrow micronucleated polychromatic erythrocytes (MnPCEs), chromosomal aberrations (CA), deoxyribonucleic acid (DNA) damage as cytogenetic markers and the levels of lipid peroxidation by-products, activities of enzymatic antioxidant and the status of detoxification agents were performed to assess the anticlastogenic effects of diosgenin on DMBA treated hamsters. Intraperitoneal injection of DMBA (30 mg/kg bw) leads to clastogenesis in hamster. Elevated MnPCEs frequencies, CA, DNA damage, enhanced lipid peroxidation by products, declined antioxidant activities and detoxification cascade were observed in DMBA treated hamsters. Oral pretreatment with diosgenin (80 mg/kg bw) daily for a period of five days significantly reduced the frequency of MnPCEs, CA, DNA damage and normalized the levels of lipid peroxidation by products with increased activities of antioxidants and detoxification agents in DMBA alone treated hamsters. Outcome of the present study revealed that diosgenin has potent anticlastogenic effects on DMBA treated hamsters.
    [Abstract] [Full Text] [Related] [New Search]